Targeting pro-dopaminergic agonism to attenuate and depression in patient's displaying genetic/epigenetic predisposition to hypodopaminergia

  • Kai Uwe Lewandrowski
  • , Kenneth Blum
  • , Alexander P.L. Lewandrowski
  • , Panayotis K. Thanos
  • , Albert Pinhasov
  • , Alireza Sharafshah
  • , David Baron
  • , Mark S. Gold
  • , Catherine A. Dennen
  • , Igor Elman
  • , Aballa Bowirrat
  • , Edward J. Modestino
  • , Foojan Zeine
  • , Nicole Jafari
  • , Keerthy Sunder
  • , Milan T. Makale
  • , John Giordano
  • , Marjorie C. Gondre-Lewis
  • , Marco Lindenau
  • , Brian S. Fuehrlein
  • Rajendra D. Badgaiyan, Chynna Levin, Sergio Luis Schmidt, Rossano Kepler Alvim Fiorelli

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Article number1594872
JournalFrontiers in Public Health
Volume13
DOIs
StatePublished - 2025
Externally publishedYes

Keywords

  • Reward Deficiency Syndrome (RDS)
  • addiction and mood disorders
  • dopamine D2 receptor (DRD2)
  • genetic predisposition
  • hypodopaminergia
  • neurotransmitter regulation
  • pro-dopaminergic therapy
  • stress induced anxiety

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this